Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size

FDA's Office of Oncology Drug Products is undergoing a reorganization aimed at making its structure more similar to the rest of the review offices in the Center for Drug Evaluation and Research